Immunodeficiency-associated lymphoproliferative disorders (Q39459): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed an Item |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| description / pt-br | description / pt-br | ||||||||||||||
A doença linfoproliferativa pós transplante (DLPT) se constitui em uma proliferação policlonal (benigna) ou clonal (maligna) de linfócitos, que se desenvolve como consequência da imunossupressão em um receptor de transplante de órgão sólido ou de medula óssea. DLPT compõem um espectro que varia de proliferação linfóide policlonal precoce induzida pelo vírus Epstein-Barr (EBV) a linfomas EBV-positivos ou EBV-negativos com predomínio de linfócitos do tipo B ou, menos comumente, do tipo T. Em outros distúrbios linfoproliferativos associados à imunossupressão, a associação com o EBV é menos pronunciada. | |||||||||||||||
| description / en | description / en | ||||||||||||||
Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV-negative lymphomas of predominantly B-cell or less often T-cell type. In other immunodeficiency-associated lymphoproliferative disorders, association with EBV is less pronounced. | |||||||||||||||
| Property / Canonical URI | |||||||||||||||
| Property / Canonical URI: https://id.who.int/icd/entity/1678636940 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / CURIE | |||||||||||||||
CID11:2B32 | |||||||||||||||
| Property / CURIE: CID11:2B32 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Canary Token | |||||||||||||||
dki-india-2B32 | |||||||||||||||
| Property / Canary Token: dki-india-2B32 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Verification Status | |||||||||||||||
Concluído | |||||||||||||||
| Property / Verification Status: Concluído / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Linked ICD 10 | |||||||||||||||
| Property / Linked ICD 10: D47.9 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 04:53, 13 August 2026
Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV-negative lymphomas of predominantly B-cell or less often T-cell type. In other immunodeficiency-associated lymphoproliferative disorders, association with EBV is less pronounced.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 2B32 |
||
| English | Immunodeficiency-associated lymphoproliferative disorders |
Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV-negative lymphomas of predominantly B-cell or less often T-cell type. In other immunodeficiency-associated lymphoproliferative disorders, association with EBV is less pronounced. |
Statements
CID11:2B32
0 references
dki-india-2B32
0 references
Concluído
0 references
13 August 2026
0 references
